Display options
Cite
Josefsson A, Wiréhn AB, Lindberg M, et al. Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010. BMJ Open. 2013;3(10):e003401doi: 10.1136/bmjopen-2013-003401.
Josefsson, A., Wiréhn, A. B., Lindberg, M., Foldemo, A., & Brynhildsen, J. (2013). Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010. BMJ open, 3(10), e003401. https://doi.org/10.1136/bmjopen-2013-003401
Josefsson, Ann, et al. "Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010." BMJ open vol. 3,10 (2013): e003401. doi: https://doi.org/10.1136/bmjopen-2013-003401
Josefsson A, Wiréhn AB, Lindberg M, Foldemo A, Brynhildsen J. Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010. BMJ Open. 2013 Oct 18;3(10):e003401. doi: 10.1136/bmjopen-2013-003401. PMID: 24141970; PMCID: PMC3808784.
Copy Download .nbib Format: NLM
Share it on

BMJ Open. 2013 Oct 18;3(10):e003401. doi: 10.1136/bmjopen-2013-003401.

Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010.

BMJ open

Ann Josefsson, Ann-Britt Wiréhn, Malou Lindberg, Anniqa Foldemo, Jan Brynhildsen

Affiliations

  1. Division of Obstetrics and Gynaecology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.

PMID: 24141970 PMCID: PMC3808784 DOI: 10.1136/bmjopen-2013-003401

Abstract

OBJECTIVE: To investigate if continuation rates in first-time users of oral hormonal contraceptives differed between different formulations and to measure if the rates were related to the prescribing categories, that is, physicians and midwives.

DESIGN: A longitudinal national population-based registry study.

SETTING: The Swedish prescribed drug register.

PARTICIPANTS: All women born between 1977 and 1994 defined as first-time users of hormonal contraceptives from 2007 to 2009 (n=226 211).

MAIN OUTCOME MEASURES: A tendency to switch the type of hormonal contraceptive within 6 months use and repeated dispensation identical to the first were estimated as percentages and relative risks (RRs). Physicians' and midwives' prescription patterns concerning the women's continuation rates of oral hormonal contraceptive type.

RESULTS: In Sweden, there were 782 375 women born between 1977 and 1994 at the time of the study. Of these, 226 211 women were identified as first-time users of hormonal contraceptives. Ethinylestradiol+levonorgestrel, desogestrel-only and ethinylestradiol+drospirenone were the hormonal contraceptives most commonly dispensed to first-time users at rates of 43.3%, 24.4% and 11.1%, respectively. The overall rate of switching contraceptive types in the first 6 months was 11.3%, which was highest for desogestrel-only (14.3%) and lowest for ethinylestradiol+drospirenone (6.6%). The switching rate for all three products was highest in the 16-year to 19-year age group. Having a repeated dispensation identical to the initial dispensation was highest for users of ethinylestradiol either combined with levonorgestrel or drospirenone, 81.4% and 81.2%, respectively, whereas this rate for the initial desogestrel-only users was 71.5%. The RR of switching of contraceptive type within the first 6 months was 1.35 (95% CI 1.32 to 1.39) for desogestrel-only and 0.63 (0.59 to 0.66) for ethinylestradiol+drospirenone compared with ethinylestradiol+levonorgestrel as the reference category. There were no differences in the women's continuation rates depending on the prescriber categories.

CONCLUSIONS: Desogestrel-only users conferred the highest switcher rate to another hormonal contraceptive within a 6-month period. Users of ethinylestradiol+levonorgestrel were more prone to switch to another product within 6 months than women using ethinylestradiol+drospirenone. These findings may be of clinical importance when tailoring hormonal contraceptives on an individual basis.

Keywords: Public Health

References

  1. Contraception. 2007 May;75(5):344-54 - PubMed
  2. Eur J Contracept Reprod Health Care. 2007 Jun;12(2):119-24 - PubMed
  3. BMJ. 2011 Apr 21;342:d2151 - PubMed
  4. Obstet Gynecol. 2011 Mar;117(3):551-557 - PubMed
  5. J Fam Plann Reprod Health Care. 2012 Jan;38(1):2-6 - PubMed
  6. J Fam Plann Reprod Health Care. 2010 Jul;36(3):123-9 - PubMed
  7. Best Pract Res Clin Obstet Gynaecol. 2009 Apr;23(2):199-209 - PubMed
  8. Cochrane Database Syst Rev. 2011 Nov 09;(11):CD003553 - PubMed
  9. Obstet Gynecol. 2006 Nov;108(5):1107-14 - PubMed
  10. Cochrane Database Syst Rev. 2011 May 11;(5):CD004861 - PubMed
  11. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35 - PubMed
  12. Contraception. 2009 Aug;80(2):163-9 - PubMed
  13. J Pediatr Adolesc Gynecol. 2011 Aug;24(4):197-203 - PubMed
  14. Contraception. 2012 Dec;86(6):653-8 - PubMed
  15. Acta Obstet Gynecol Scand. 2012 Jul;91(7):769-78 - PubMed
  16. Acta Obstet Gynecol Scand. 2012 Jul;91(7):810-5 - PubMed
  17. BMJ. 2011 Apr 21;342:d2139 - PubMed
  18. Am J Obstet Gynecol. 1992 Feb;166(2):578-83 - PubMed
  19. J Fam Plann Reprod Health Care. 2010 Jan;36(1):33-8 - PubMed
  20. BMJ. 2012 May 10;344:e2990 - PubMed
  21. Cochrane Database Syst Rev. 2004;(3):CD004861 - PubMed
  22. Contraception. 2008 Apr;77(4):257-63 - PubMed

Publication Types